Breaking News Headlines Today | Ground News

See every side of every news story

lifesciencesbc.ca image

News from lifesciencesbc.ca

Ground News rates lifesciencesbc.ca’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

lifesciencesbc.ca’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about lifesciencesbc.ca

Where is lifesciencesbc.ca located?lifesciencesbc.ca's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top lifesciencesbc.ca News

AbbVie Breaks Ground on North Chicago Manufacturing Facility - Chicago ...

North Chicago · North Chicago

AbbVie Breaks Ground on North Chicago Manufacturing Facility - Chicago ...

100% Center coverage: 8 sources

New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicinesFacility expected to be fully operational and serving patients by 2027Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing See the Story

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

Influenza · United States

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

100% Center coverage: 8 sources

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...See the Story

First-Ever IL-23 Inhibitor: J&J's TREMFYA Approved for Children with Psoriasis, Shows 56% Clearance Rate

Johnson & Johnson · United States

First-Ever IL-23 Inhibitor: J&J's TREMFYA Approved for Children with Psoriasis, Shows 56% Clearance Rate

FDA approves TREMFYA for children 6+ with plaque psoriasis and psoriatic arthritis. Study shows 56% achieved PASI 90 vs 16% placebo. Impacts 20,000 children under 10 annually.See the Story

Breaking News Topics Related to lifesciencesbc.ca